![](https://endpts.com/wp-content/uploads/2022/03/Adam-Simpson-scaled.jpg)
Adam Simpson, Icosavax CEO
Icosavax discovers what caused its lead vaccine to flop, and doesn't see it affecting follow-up programs
Seattle-based Icosavax was one of the companies in the rat race to develop Covid-19 vaccine shots better than Pfizer and Moderna. However, when clinical trials …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.